El tratamiento con quimioterapia hoy en pacientes HER2 negativo: el papel de la eribulina - page 7

BC Therapies Timeline (FDA)
Harris et al. Diseases of the Breast 2010 (4
th
edition)
1953
MTX
1959
CF
1962
5FU
1963
Vincristin
1974
Mitomycin,
Doxorubicin
1978
CDDP
1989
Carboplatin
1994
Paclitaxel
1996
Docetaxel
1998
Capecitabine
1
999
Epirubicin
Vinorelbine
End HDCT
2002
Liposomal-Doxo
2004
Gemcitabine
2005
Nab-paclitaxel
2007
Ixabepilone
1977
Tamoxifen
1995
Goserelin
1996
Anastrozol
e
1997
Letrozole
1998
Pamidronate
Trastuzumab
1999
Exemestane
2001
Zoledronic Ac
2002
Fulvestrant
2007
Lapatinib
2008
Bevacizumab
1896
Ovarian Ablation
1922
Ovarian RT
1938
Androgens
1944
Estrogens
1951
Progestins
1952
Hypophysectomy
1953
Adrenalectomy
2011
Eribulin
2012
Pertuzumab
Everolimus
2013
Denosumab
T-DM1
2015
Palbociclib
1,2,3,4,5,6 8,9,10,11,12,13,14,15,16,17,...43
Powered by FlippingBook